ATLANTA, Ga., March 12, 2025 – Odylia Therapeutics, a nonprofit biotechnology company dedicated to advancing treatments for rare diseases, is pleased to announce the appointment of Joy Cavagnaro to its Board of Directors.

Dr. Cavagnaro brings a wealth of expertise in preclinical development and regulatory science, with almost 40 years of experience in thebiotechnology industry. As the Founder and President of Access BIO, she has been instrumental in shaping science-based strategies for preclinical development of novel biological therapies. Her distinguished career includes serving as a member of the Senior Biomedical Research Service at the U.S. Food and Drug Administration (FDA) and chairing pivotal working groups that have influenced regulatory guidance.

Dr. Cavagnaro has also been a longstanding contributor to Odylia’s mission, having served on the Board of Advisors for the past seven years. During this time, she played a vital role in shaping Odylia’s strategic direction and fostering key collaborations to advance its work in the rare disease space.

In addition to her professional achievements, Dr. Cavagnaro has been actively involved for over 20 years in Special Olympics, contributing her time and energy as a multi-sport coach, mentor and member of the Board of Directors of Special Olympics Virginia helping athletes with intellectual disabilities realize their boundless possibilities.

“We are thrilled to welcome Dr. Cavagnaro to our Board of Directors,” said Ashley Winslow, CEO and Chief Scientific Officer at Odylia Therapeutics. “Her unparalleled expertise, years of dedication to Odylia, and commitment to advancing innovative therapies align perfectly with Odylia’s mission to bring hope and solutions to patients with rare diseases.”

Dr. Cavagnaro’s appointment underscores Odylia’s commitment to assembling a team of visionary leaders who are passionate about transforming the landscape of rare disease treatment. Her insights and leadership will play a critical role in guiding Odylia’s strategic initiatives and fostering collaborations that accelerate the development of life-changing therapies.

“I am honored to join the Board of Directors at Odylia Therapeutics,” said Dr. Cavagnaro. “Having served on the Board of Advisors for seven years, I am excited to deepen my involvement with this extraordinary organization and continue supporting Odylia’s mission by advocating for creative, rational, science-driven, experienced-based solutions to address the unmet needs of patients with rare diseases.”

—

Media Contact:

For media inquiries, please contact:
Odylia Media
info@odylia.org

Odylia Therapeutics is a nonprofit biotechnology company dedicated to developing and advancing treatments for rare diseases. Through deep drug development expertise, innovative research, strategic collaborations, and patient-focused initiatives, Odylia works to overcome barriers to treatment development and bring new hope to patients around the world. Odylia partners with patient communities, researchers, clinicians, industry, and financial donors to bring promising therapeutics to clinical trials. In addition to three gene therapies in development, Odylia partners with rare disease patient groups, early-stage biotechs, and academic researchers to further rare disease drug development efforts through Odylia’s Brydge Solutions program. Patient groups, companies, and researchers interested in learning more about Odylia Therapeutics’ services can email info@odylia.org and follow Odylia on LinkedIn (Odylia Therapeutics), Instagram (@OdyliaTx), and YouTube (@OdyliaTx), and Facebook (Odylia Therapeutics). For additional information, visit https://odylia.org.